Innoviva, Inc.
Innoviva, Inc. (Nasdaq: INVA) is a diversified biopharmaceutical company with a respiratory royalty portfolio, a critical care and infectious disease business, and strategic healthcare investments. It receives royalties from GSK sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA, medicines for respiratory conditions… From the company’s description.
Over the twelve months to Sep 30, 2026, Innoviva, Inc. reported revenue of $438.32M, up 12.8% from a year earlier, and net income of $193.44M. Its operating margin was 38.8%, and operations generated $183.47M in cash. In fiscal 2025, it reported revenue of $411.33M, up 14.7% from fiscal 2024, and net income of $271.17M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Innoviva, Inc. does
In the company’s own words
Innoviva, Inc. (Nasdaq: INVA) is a diversified biopharmaceutical company with a respiratory royalty portfolio, a critical care and infectious disease business, and strategic healthcare investments. It receives royalties from GSK sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA, medicines for respiratory conditions including COPD and asthma. Its wholly owned Innoviva Specialty Therapeutics platform commercializes five products focused on hospital care and infectious diseases: GIAPREZA for distributive shock, XACDURO for certain hospital-acquired and ventilator-associated pneumonias, XERAVA for complicated intra-abdominal infections, ZEVTERA for specified bloodstream, skin and respiratory infections, and NUZOLVENCE for uncomplicated gonorrhea. The company also holds a significant stake in Armata Pharmaceuticals and economic interests in other healthcare companies. Its critical care and infectious disease portfolio was established through the 2022 acquisitions of Entasis Therapeutics and La Jolla Pharmaceutical and expanded through a U.S. license for ZEVTERA. Innoviva’s business therefore combines partnered-product royalties with commercial medicines and healthcare investments. Its website is <URL>.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURLINGAME, CA
- Fiscal year end
- December
- CIK
- 1080014
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Innoviva, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Innoviva, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Innoviva, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Innoviva, Inc.’s debt, $15.80M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.13%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Innoviva, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Innoviva, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Innoviva, Inc.'s last four quarterly filings that the numbers alone won't show?”